# EDGAR Filing Document

**Accession Number:** 0001633927
**File Stem:** 0001641172-25-025004
**Filing Date:** 2025-8
**Character Count:** 5370
**Document Hash:** cb7fe0398bbe08f9dc2a28c7631c9c6b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-025004.hdr.sgml**: 20250820

**ACCESSION NUMBER**: 0001641172-25-025004

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20250409

**FILED AS OF DATE**: 20250820

**DATE AS OF CHANGE**: 20250820

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** LoPriore Vincent S
- **CENTRAL INDEX KEY:** 0001633927

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41210
- **FILM NUMBER:** 251238184

**MAIL ADDRESS:**
- **STREET 1:** 40 WALL STREET, 30TH FLOOR
- **STREET 2:** C/O CENTRAL PARK ADVISORS, LLC
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10005
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Tharimmune, Inc.
- **CENTRAL INDEX KEY:** 0001861657
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842642541
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 ROUTE 22 EAST
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
- **BUSINESS PHONE:** 302-743-2995

**MAIL ADDRESS:**
- **STREET 1:** 245 MAIN STREET
- **STREET 2:** SUITE 204
- **CITY:** CHESTER
- **STATE:** NJ
- **ZIP:** 07930

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tharimmune, Inc
- **DATE OF NAME CHANGE:** 20230925

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Hillstream BioPharma Inc.
- **DATE OF NAME CHANGE:** 20210511

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>LoPriore Vincent S<br><sub>(Last) (First) (Middle)</sub><br>C/O THARIMMUNE, INC.<br>34 SHREWSBURY AVE., SUITE 1C<br><sub>(Street)</sub><br>RED BANK, NJ 07701<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Tharimmune, Inc. [ THAR ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-04-09 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [X] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Executive Chairman_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 732424 | I | By Gravitas Capital LP<sup>(1)</sup> |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Stock Option (right to buy) | <sup>(2)</sup> | 2035-08-04 | Common Stock | 100000 | $1.33 | D |  |
| Series A Warrants (right to buy) | 2025-12-20 | 2030-12-20 | Common Stock | 337838 | $1.29 | I | See Footnote<sup>(1)</sup> |
| Series B Warrants (right to buy) | 2025-12-20 | 2030-12-20 | Common Stock | 168918 | $3.00 | I | See Footnote<sup>(1)</sup> |
| Common Stock Purchase Warrants | 2025-06-09 | 2030-06-09 | Common Stock | 443806 | $2.03 | I | See Footnote<sup>(1)</sup> |

---

### Footnotes:

(1) The reported shares are owned directly by Gravitas Capital LP, a limited partnership of which Gravitas Capital Partners LLC is the sole general partner. The reporting person is the managing member of Gravitas Capital Partners LLC. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.

(2) 50,000 of the options vest on date of grant and 50,000 vest on August 4, 2026.

**Signature:** /s/ Vincent S. LoPriore  
**Date:** 2025-08-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**